The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
This certification will open new markets for the Kwality Pharma
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
The company has received the GMP Certification after successful closure of the inspection
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Subscribe To Our Newsletter & Stay Updated
